Cargando…

Pazopanib diminishes non-small cell lung cancer (NSCLC) growth and metastases in vivo

BACKGROUND: Anti-angiogenesis has been demonstrated to have a critical role in lung cancer pathogenesis. Here, we characterized the effect of the small-molecule angiogenesis inhibitor pazopanib on non-small cell lung cancer (NSCLC) cells. METHODS: NSCLC cells were tested for viability and migration...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Honglin, Yang, Fan, Shen, Wang, Wang, Yuli, Li, Xuebing, You, Jiacong, Zhou, Qinghua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2015
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4448486/ https://www.ncbi.nlm.nih.gov/pubmed/26273349 http://dx.doi.org/10.1111/1759-7714.12138

Ejemplares similares

Successful Treatment with Pazopanib for Multiple Lung Metastases of Inguinal Epithelioid Sarcoma: A Case Report
por: Irimura, Sanae, et al.
Publicado: (2015)

MiR-132 Suppresses the Migration and Invasion of Lung Cancer Cells via Targeting the EMT Regulator ZEB2
por: You, Jiacong, et al.
Publicado: (2014)

Pazopanib for Non-small Cell Lung Cancer: The First Case Report in Korea
por: Jo, Jaemin, et al.
Publicado: (2016)

TSPAN12 is overexpressed in NSCLC via p53 inhibition and promotes NSCLC cell growth in vitro and in vivo
por: Hu, Zhongwu, et al.
Publicado: (2018)

Interstitial Lung Disease Induced by Pazopanib Treatment
por: Ide, Shotaro, et al.
Publicado: (2017)

Development of epidermal growth factor receptor tyrosine kinase inhibitors against EGFR T790M. Mutation in non small-cell lung carcinoma
por: Wang, Yuli, et al.
Publicado: (2016)

EGFR-Driven Mutation in Non-Small-Cell Lung Cancer (NSCLC) Influences the Features and Outcome of Brain Metastases
por: Armocida, Daniele, et al.
Publicado: (2023)

Real‐world treatment and prognostic factors for survival in ALK+ non‐small cell lung cancer (NSCLC) patients with brain metastases in China
por: Li, Na, et al.
Publicado: (2022)

Pneumothorax as adverse event in patients with lung metastases of soft tissue sarcoma treated with pazopanib: a single reference centre case series
por: Verschoor, Arie J, et al.
Publicado: (2014)

Pazopanib restricts small cell lung cancer proliferation via reactive oxygen species‐mediated endoplasmic reticulum stress
por: Li, Yue, et al.
Publicado: (2022)

Effects of Pazopanib Monotherapy vs. Pazopanib and Topotecan Combination on Anaplastic Thyroid Cancer Cells
por: Di Desidero, Teresa, et al.
Publicado: (2019)

Pazopanib and anti-VEGF therapy
por: Drabkin, Harry A
Publicado: (2010)

Pazopanib and Statin-Induced Rhabdomyolysis
por: Logue, Jennifer M., et al.
Publicado: (2017)

Phototoxic Reaction Induced by Pazopanib
por: Udompanich, Siriorn, et al.
Publicado: (2018)

Tension Pneumothorax: Is it Sarcoma or Pazopanib?
por: Sebanayagam, Vinoja, et al.
Publicado: (2020)

Immunotherapy in NSCLC Patients with Brain Metastases
por: Buriolla, Silvia, et al.
Publicado: (2022)

ZD 1839 in patients with brain metastases from non-small-cell lung cancer (NSCLC): report of four cases
por: Cappuzzo, F, et al.
Publicado: (2003)

Pazolimus: pazopanib plus sirolimus following progression on pazopanib, a retrospective case series analysis
por: Katz, D., et al.
Publicado: (2016)

Mg-based materials diminish tumor spreading and cancer metastases
por: Globig, Philipp, et al.
Publicado: (2022)

Clinical Activity of Pazopanib in Patients with Advanced Desmoplastic Small Round Cell Tumor
por: Menegaz, Brian A., et al.
Publicado: (2017)

Activity of crizotinib over choroidal metastases in Non-Small-Cell Lung Cancer (NSCLC)-ALK rearranged: a case report
por: Bearz, Alessandra, et al.
Publicado: (2014)

The Surgical Management of Brain Metastases in Non-Small Cell Lung Cancer (NSCLC): Identification of the Early Laboratory and Clinical Determinants of Survival
por: Schneider, Matthias, et al.
Publicado: (2021)

The Prognostic Value of Periostin Expression in Non-Small Cell Lung Cancer: A Meta-Analysis
por: Li, Mengjie, et al.
Publicado: (2022)

Pazopanib radio-sensitization of human sarcoma tumors
por: Wang, Feng, et al.
Publicado: (2018)

Association between P(16INK4a) Promoter Methylation and Non-Small Cell Lung Cancer: A Meta-Analysis
por: Gu, Jundong, et al.
Publicado: (2013)

Efficacy of dacomitinib in patients with EGFR‐mutated NSCLC and brain metastases
por: Zhang, Jinyao, et al.
Publicado: (2021)

Inhibition of non-small cell lung cancer (NSCLC) growth by a novel small molecular inhibitor of EGFR
por: Li, Jinsong, et al.
Publicado: (2015)

Immunotherapy in NSCLC Patients With Brain and Leptomeningeal Metastases
por: Pierret, Thomas, et al.
Publicado: (2022)

Pazopanib: Approval for Soft-Tissue Sarcoma
por: Nguyen, Diana T., et al.
Publicado: (2013)

Pazopanib for the treatment of soft-tissue sarcoma
por: Heudel, Pierre, et al.
Publicado: (2012)

Pazopanib induced hand-foot syndrome
por: Sundriyal, Deepak, et al.
Publicado: (2015)

Pazopanib-Induced Alopecia, an Underestimated Toxicity?
por: Biondo, Andrea, et al.
Publicado: (2015)

Pazopanib-Induced Severe Acute Pancreatitis
por: Kawakubo, Kazumichi, et al.
Publicado: (2015)

Thrombotic Thrombocytopenic Purpura Associated with Pazopanib
por: Syed, Umer, et al.
Publicado: (2018)

Pazopanib in advanced soft tissue sarcomas
por: Lee, Alex T. J., et al.
Publicado: (2019)

Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC)
por: O’Leary, Connor, et al.
Publicado: (2020)

Staging of non-small cell lung cancer (NSCLC)
por: Rankin, S C
Publicado: (2006)

The microRNA miR-34a Inhibits Non-Small Cell Lung Cancer (NSCLC) Growth and the CD44(hi) Stem-Like NSCLC Cells
por: Shi, Yang, et al.
Publicado: (2014)

Rapid and life-threatening heart failure induced by pazopanib
por: Wang, Haotong, et al.
Publicado: (2018)

Pazopanib in advanced desmoplastic small round cell tumours: a multi-institutional experience
por: Frezza, Anna Maria, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_bhdkr3f9mvt3ieens0pp81mjhd